Profile picture of Joanne Tang

Dr Joanne Tang

Profile picture of Joanne Tang

FRACP, MPH, MBBS, Clin Dip (Pall Med)

Medical Oncologist
Call
Enquire
Referrals
Adelaide (Kurralta Park)
08 8450 3375

Dr Joanne Tang is a thoughtful and dedicated medical oncologist who strives to provide personalised, evidence-based care that supports the whole person. She has a strong interest in clinical trials and is passionate about using research to improve access to emerging treatments and outcomes for patients. Dr Tang believes in partnering closely with each patient to ensure care is aligned with their goals, values and wellbeing.

Biography

Dr Joanne Tang is a medical oncologist at Icon Cancer Centre Adelaide (Kurralta Park) and Icon Cancer Centre Windsor Gardens. She completed her Bachelor of Medicine and Bachelor of Surgery at the University of Tasmania, where she was awarded a Clinical Distinction Award and a Cochrane Airways Australia Satellite Scholarship for her research contributions. She went on to complete her specialist training in medical oncology at major tertiary hospitals including the Royal Adelaide Hospital, Queen Elizabeth Hospital, Royal Darwin Hospital and Calvary Adelaide, earning Fellowship with the Royal Australasian College of Physicians in 2024.

Dr Tang also holds a Master of Public Health in Epidemiology and a Clinical Diploma in Palliative Care, equipping her with a holistic approach to patient care that integrates symptom control, quality of life and long-term outcomes. She has contributed to more than 30 clinical trials as a sub-investigator, spanning gastrointestinal, genitourinary, breast, skin, thoracic and central nervous system cancers, as well as early phase research. Her clinical trial work includes first-in-human studies and biomarker-driven treatments, reflecting her strong commitment to translational oncology.

She has published widely in peer-reviewed journals and presented research at national and international conferences, including the Medical Oncology Group of Australia (MOGA) and the European Society for Medical Oncology (ESMO). Her research has covered diverse topics such as the value of systemic therapies, treatment outcomes in early phase trials and patient-reported health measures. In 2024, she was selected to attend the ACORD Protocol Development Workshop, furthering her skills in clinical trial design.

In addition to her clinical and research roles, Dr Tang is an active educator. She is a Conjoint Associate Lecturer with the University of New South Wales and previously held a teaching position with the University of Adelaide, providing mentorship and bedside teaching to medical students and trainees across all stages of their learning.

Publications

  • Tang J, Stein BN. Benefit of standard systemic treatments of solid tumours in Australia varies by indication, tumour stream, and treatment modality. ESMO Real World Data and Digital Oncology 2025; 8.

  • Nindra U, Tang J, Hong JH, et al. Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study. JNCI Cancer Spectr 2025; 9(2).

  • Shahnam A, Nindra U, Hitchen N, Tang J, Hong M, Hong JH, Au-Yeung G, Chua W, Ng W, Hopkins AM, Sorich MJ. Application of Generative Artificial Intelligence for Physician and Patient Oncology Letters-AI-OncLetters. JCO Clin Cancer Inform. 2025 May;9:e2400323. doi: 10.1200/CCI-24-00323.

  • Tang J, Nindra U, Hong JH, Hong M, Lemech, C, Teng C, et al. Early change in Patient Reported Global Health Status Scores predicts Treatment Response in Early Phase Clinical Trials: a PEARLER sub-study. MOGA Annual Scientific Meeting; 2024; Sydney, New South Wales; 2024. [Poster Presentation]

  • Tang J, Selva-Nayagam S. Safety and Tolerability of Reversed Sequencing and the Use of Weekly Cisplatin Chemoradiotherapy in the Adjuvant Treatment of Endometrial Cancer. MOGA Annual Scientific Meeting; 2023; Perth, Western Australia; 2023. Poster Presentation]

Special Interests

Dr Joanne Tang accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Head and neck cancer
  • Thoracic cancer

Languages spoken

  • English
  • Mandarin

Publications

  • Tang J, Stein BN. Benefit of standard systemic treatments of solid tumours in Australia varies by indication, tumour stream, and treatment modality. ESMO Real World Data and Digital Oncology 2025; 8.

  • Nindra U, Tang J, Hong JH, et al. Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study. JNCI Cancer Spectr 2025; 9(2).

  • Shahnam A, Nindra U, Hitchen N, Tang J, Hong M, Hong JH, Au-Yeung G, Chua W, Ng W, Hopkins AM, Sorich MJ. Application of Generative Artificial Intelligence for Physician and Patient Oncology Letters-AI-OncLetters. JCO Clin Cancer Inform. 2025 May;9:e2400323. doi: 10.1200/CCI-24-00323.

  • Tang J, Nindra U, Hong JH, Hong M, Lemech, C, Teng C, et al. Early change in Patient Reported Global Health Status Scores predicts Treatment Response in Early Phase Clinical Trials: a PEARLER sub-study. MOGA Annual Scientific Meeting; 2024; Sydney, New South Wales; 2024. [Poster Presentation]

  • Tang J, Selva-Nayagam S. Safety and Tolerability of Reversed Sequencing and the Use of Weekly Cisplatin Chemoradiotherapy in the Adjuvant Treatment of Endometrial Cancer. MOGA Annual Scientific Meeting; 2023; Perth, Western Australia; 2023. Poster Presentation]

Search

Contact us
Become a patient